Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
weight drugs
Biotech
Novo inks $1B deal for Lexicon’s preclinical obesity prospect
Novo is betting $75 million in upfront and near-term milestone payments for rights to a preclinical asset that paired well with semaglutide in mice.
Nick Paul Taylor
Mar 28, 2025 7:30am
Roche pays Zealand $1.6B to codevelop amylin obesity asset
Mar 12, 2025 5:23am
Ascletis continues obesity surge with competitive GLP-1 data
Feb 19, 2025 10:35am
Viking's GLP-1 spurs steep weight loss, sending shares up 80%
Feb 27, 2024 10:15am
AstraZeneca CEO: GLP-1 focus is weight management, not obesity
Nov 10, 2023 12:08pm
This cancer-related gene may also help combat obesity
May 22, 2020 8:35am
